Apoptosis and BCL-2

Share this animation:

ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptopic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.

Share It:
Contact XVIVO


Abbvie; Genentech

I have had the pleasure of working closely with the XVIVO team for the past year and half as we prepared for launch. They have contributed to building a sound foundation for communicating our clinical messaging across multiple mediums and channels. XVIVO’s scientific rigor and technical expertise exceed any I have seen within the industry. The XVIVO team consists of highly professional engaging personnel that have mastered their respective areas of work. XVIVO are fun and engaging partners. The products that XVIVO consistently delivered elevated the power of our story.

Intuniv Marketing, Shire LLC.
Share this animation: